Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2026-06-08 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a formal Notice of Annual General Meeting sent to shareholders, listing resolutions to be voted on and instructions for appointing proxies and attending the meeting. This is part of the proxy solicitation and information statement materials distributed to shareholders prior to a meeting, rather than the AGM presentation itself or the annual report. Therefore, it best fits the Proxy Solicitation & Information Statement category (PSI).
2026-06-08 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 30, 2026
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a ‘Form of Proxy for the Annual General Meeting,’ which is sent to shareholders to appoint proxies and instruct votes at the AGM. It is not the annual report itself nor an earnings release, but rather proxy solicitation material. This aligns with the Proxy Solicitation & Information Statement (PSI) category.
2026-06-08 English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED ELECTION OF DIRECTOR; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular for Ocumension Therapeutics’ Annual General Meeting, containing: notice of meeting, explanatory statements on AGM resolutions (general mandates to issue/repurchase shares, director re-elections, auditor appointment, scheme refreshment), proxy form instructions, and voting procedures. It is a solicitation of proxies and information statement sent to shareholders to request their votes. This aligns with Proxy Solicitation & Information Statement (PSI).
2026-06-08 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2026
Regulatory Filings Classification · 88% confidence The document is a mandatory monthly return filed by a Hong Kong listed issuer (Ocumension Therapeutics) under HKEX Listing Rules Chapter 19B, detailing movements in share capital, issued shares, treasury shares, share option schemes, and confirmations. It is a recurring regulatory compliance submission rather than a financial report, earnings release, or any corporate action announcement like M&A or director dealings. Therefore, it falls under the general Regulatory Filings category (RNS) as a listing-rule compliance document.
2026-06-04 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-802
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement issued on the Hong Kong Exchange regarding the first patient enrollment in a Phase III clinical trial. It is not an annual or interim financial report, earnings release, director change, share issue, dividend notice, corporate presentation, or any other specific filing type. It is a miscellaneous business/regulatory update. According to the fallback category definition, this should be classified as a general Regulatory Filing (RNS).
2026-05-28 English
GRANTS OF OPTIONS AND AWARDS
Share Issue/Capital Change Classification · 78% confidence The document is a public regulatory announcement under the Hong Kong Listing Rules disclosing the details of grants of share options and share awards under the Company’s 2021 Share Option Scheme and 2021 Share Award Scheme. It is not a financial report, earnings release, management discussion, or remuneration proxy statement, nor is it an insider personal trade (DIRS) or share buy-back (POS). It represents a capital change – the grant of rights to subscribe for new shares – and thus best fits our Share Issue/Capital Change category (Code: SHA).
2026-05-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.